Media Articles Related to Ellence (Epirubicin)
NICE Endorses Integrated Glucose Management Technology
Source: Medscape Diabetes & Endocrinology Headlines [2015.08.25]
Draft guidance from the UK National Institute for Health and Care Excellence recommends Medtronic's Veo System for type 1 diabetes patients who experience severe hypoglycemia.
Medscape Medical News
Fighting infection: NICE tackles overuse of antibiotics
Source: Primary Care / General Practice News From Medical News Today [2015.08.18]
The National Institute for Health and Care Excellence (NICE) has published guidance to help doctors, nurses and pharmacists promote and monitor the sensible use of antimicrobials - a group of...
NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Source: Stroke News From Medical News Today [2015.08.07]
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help prevent strokes and systemic embolism in patients suffering from the heart rhythm disorder...
Lung cancer: final NICE guidance recommends Vargatef (nintedanib) in combination with docetaxel
Source: Lung Cancer News From Medical News Today [2015.07.23]
The National Institute for Health and Care Excellence (NICE) has issued its final Technology Appraisal Guidance recommending Vargatef® (nintedanib) in combination with docetaxel as an option...
Oncotype DX Impacts Chemotherapy Decisions in Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2015.08.28]
A large cohort study demonstrated that Oncotype DX testing was associated with less frequent chemotherapy use in high-risk patients, but more frequent use in low-risk women.
Medscape Medical News
Published Studies Related to Ellence (Epirubicin)
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. [2011.08.20]
PURPOSE: The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer... CONCLUSION: These results suggest, within a relatively small trial, that substitution of docetaxel for epirubicin for the last three cycles of chemotherapy results in improved outcome in postmenopausal women with node-positive, early breast cancer compared with six cycles of epirubicin monotherapy.
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. [2011.07]
An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-escalation) or by shortening the interval between cycles (dose-dense). This multicenter randomized phase II study assessed the efficacy and safety of two different approaches: epirubicin 110 mg/m(2) combined with paclitaxel 200 mg/m(2) every 21 days and epirubicin 75 mg/m(2) combined with paclitaxel 175 mg/m(2) every 10 days, both supported with G-CSF...
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. [2011.04.27]
CONCLUSION: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy. In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. [2011.02.15]
BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients... CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.
Clinical Trials Related to Ellence (Epirubicin)
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer [Terminated]
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving epirubicin together with vinorelbine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving epirubicin together with
vinorelbine works in treating patients with stage II, stage III, or stage IV breast cancer.
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer [Active, not recruiting]
This phase I clinical trial studies the side effects and the best dose of dinaciclib when
given together with epirubicin hydrochloride (epirubicin) in patients with metastatic
(cancer that has spread to other parts of the body) triple-negative breast cancer.
Dinaciclib is designed to stop cancer cells from dividing into new cancer cells. Epirubicin
is designed to block the way cancer cells grow and divide and may slow or stop cancer cells
from spreading throughout the body. Researchers want to find out what is the highest
tolerable dose of the experimental drug dinaciclib that can be given in combination with
epirubicin in patients with metastatic triple negative breast cancer.
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors [Completed]
This is an open-label, four-arm, Phase I, dose escalation study to evaluate the safety and
tolerability and to determine the optimal tolerated regimen (OTR) of pazopanib in
combination with epirubicin or doxorubicin in patients with advanced solid tumors. Patients
will be enrolled in cohorts of 3 to receive escalating doses of pazopanib and epirubicin or
doxorubicin. Dose escalation schemas for each study arm are described in the protocol. For
each arm, the OTR will be defined as the highest dose combination of the agents where no
more than one out of six patients experiences a dose-limiting toxicity. Twelve additional
patients in each arm will be studied with the OTR to evaluate toxicity and pharmacokinetics.
This will allow an assessment of potential drug-drug interactions. Antitumor activity will
be assessed using RECIST criteria.
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer [Completed]
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the
biweekly pegfilgrastim support, in order to further improve upon the effectiveness and
favorable toxicity of this triplet.
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer [Recruiting]
Molecular markers predicting response to dose dense chemotherapy with epirubicin and
docetaxel in sequence for locally advanced breast cancer
Principal Investigator Per E Lonning, Professor, Section of Oncology, Department of Medicine
Collaborators. Dept of Surgery - Responsible: Turid Aas, Consultant Surgeon Dept of
Molecular Biology - Responsible: Professor Johan Lillehaug Dept of Anatomy and Cellular
Biology - Responsible: Professor Rolf Bjerkvig
Participants. Dept of Oncology Gun Anker, Consultant Oncologist Stephanie Geisler,
Consultant Oncologist Jurgen Geisler, Consultant Oncologist
Type of Study Phase II, Translational research
Scientific aims: Addressing factors predicting response to dose intensive epirubicin
followed by docetaxel sequential therapy
Treatment regimen: epirubicin 60 mg/m2 on a 2 weekly basis x 4 followed by docetaxel 100
mg/m2 2-weekly x 4.
Patients: Breast cancer patients below 65 years of age suffering from large (>4 cm largest
diameter, non-inflammatory and / or N2-N3) primary breast cancer.
Clinical aim: Assessing responsiveness to this dose intensive regimen.
Number of patients to be enrolled: 60 - 100
Reports of Suspected Ellence (Epirubicin) Side Effects
Disease Progression (2),
Oesophageal Carcinoma (2),
Orthostatic Hypotension (1),
Pulmonary Embolism (1),
Loss of Consciousness (1),
Cardio-Respiratory Arrest (1),
Pleural Effusion (1),
Myocardial Infarction (1), more >>